COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view.
作者信息
Vitiello Antonio, Porta Raffaele La, Pianesi Laura, Ferrara Francesco
机构信息
Pharmaceutical Department Usl Umbria 1, Perugia, Italy.
Pathology Department ASUR Marche, Area Vasta 1, Urbino, Italy.
出版信息
Ir J Med Sci. 2022 Feb;191(1):487-488. doi: 10.1007/s11845-021-02584-5. Epub 2021 Mar 12.
Abstract
摘要
相似文献
1
COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view.2019冠状病毒病大流行：疫苗与新型单克隆抗体，观点
Ir J Med Sci. 2022 Feb;191(1):487-488. doi: 10.1007/s11845-021-02584-5. Epub 2021 Mar 12.
2
The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.SARS-CoV-2 变异株的出现威胁到中和抗体和疫苗的效力。
Biochem Soc Trans. 2021 Dec 17;49(6):2879-2890. doi: 10.1042/BST20210859.
3
A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.COVID-19 中单抗的研究进展：在免疫治疗、疫苗开发和病毒检测中的作用。
Hum Antibodies. 2021;29(3):179-191. doi: 10.3233/HAB-200441.
4
COVID-19 global pandemic: vaccines and new monoclonal antibodies, aspects to be clarified.新型冠状病毒肺炎全球大流行：疫苗与新型单克隆抗体，有待阐明的方面。
Immunol Res. 2021 Apr;69(2):115-116. doi: 10.1007/s12026-021-09193-5. Epub 2021 Apr 15.
5
Vaccines, convalescent plasma, and monoclonal antibodies for covid-19.用于治疗新冠病毒病的疫苗、康复期血浆和单克隆抗体。
BMJ. 2020 Jul 9;370:m2722. doi: 10.1136/bmj.m2722.
6
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗：全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
7
Audio Interview: Planning for the SARS-CoV-2 Vaccine Rollout.音频访谈：SARS-CoV-2疫苗接种计划
N Engl J Med. 2021 Jan 7;384(1):e13. doi: 10.1056/NEJMe2100295.
8
Stopping pandemics before they start: Lessons learned from SARS-CoV-2.在疫情爆发前就阻止它们：从 SARS-CoV-2 中吸取的教训。
Science. 2022 Mar 11;375(6585):1133-1139. doi: 10.1126/science.abn1900. Epub 2022 Mar 10.
9
COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics).COVID-19 治疗药物：用途、作用机制和毒性（疫苗、单克隆抗体和免疫疗法）。
J Med Toxicol. 2023 Apr;19(2):205-218. doi: 10.1007/s13181-023-00931-9. Epub 2023 Mar 2.
10
Vaccines against SARS-CoV-2 variants and future pandemics.针对 SARS-CoV-2 变体和未来大流行的疫苗。
Expert Rev Vaccines. 2022 Oct;21(10):1363-1376. doi: 10.1080/14760584.2022.2110075. Epub 2022 Aug 12.
引用本文的文献
1
The influence of Omicron on vaccine efficacy and durability: a neurology perspective.奥密克戎对疫苗效力和持久性的影响：神经学视角
Clin Exp Vaccine Res. 2024 Jul;13(3):175-183. doi: 10.7774/cevr.2024.13.3.175. Epub 2024 Jul 31.
2
SARS-CoV-2 caused a surge in antibiotic consumption causing a silent pandemic inside the pandemic. A retrospective analysis of Italian data in the first half of 2022.SARS-CoV-2 导致抗生素消耗量激增，在大流行期间引发了一场无声的大流行。对 2022 年上半年意大利数据的回顾性分析。
Ann Pharm Fr. 2023 Jun;81(4):627-635. doi: 10.1016/j.pharma.2023.02.003. Epub 2023 Feb 28.
3
Long COVID could become a widespread post-pandemic disease? A debate on the organs most affected.长新冠可能成为一种广泛流行的后疫情疾病？关于受影响最严重的器官的争论。
Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1583-1589. doi: 10.1007/s00210-023-02417-5. Epub 2023 Feb 11.
4
The direct correlation between microbiota and SARS-CoV-2 infectious disease.肠道微生物群与 SARS-CoV-2 传染病之间的直接相关性。
Inflammopharmacology. 2023 Apr;31(2):603-610. doi: 10.1007/s10787-023-01145-9. Epub 2023 Feb 1.
5
Pharmacological Agents with Antiviral Activity against Monkeypox Infection.具有抗猴痘感染病毒活性的药物制剂。
Int J Mol Sci. 2022 Dec 14;23(24):15941. doi: 10.3390/ijms232415941.
6
What Do We Know About the Smallpox Virus? A Journey Between Clinic and Therapy.我们对天花病毒了解多少？一次从临床到治疗的探索之旅。
Pharm Res. 2023 Feb;40(2):459-465. doi: 10.1007/s11095-022-03447-z. Epub 2022 Nov 30.
7
COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.COVID-19 mRNA 疫苗：一项回顾性观察性药物警戒研究。
Clin Drug Investig. 2022 Dec;42(12):1065-1074. doi: 10.1007/s40261-022-01216-9. Epub 2022 Oct 23.
8
Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.尼马曲韦-瑞德西韦联合治疗非住院 COVID-19 成人患者：观点。
Inflammopharmacology. 2022 Oct;30(5):1927-1931. doi: 10.1007/s10787-022-01055-2. Epub 2022 Aug 18.
9
Could Decreased Reporting of Suspected Adverse Reactions Generate Future Safety Concerns?疑似不良反应报告的减少会引发未来的安全担忧吗？
Hosp Pharm. 2022 Aug;57(4):419-421. doi: 10.1177/00185787211069040. Epub 2022 Jan 7.
10
Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.妊娠与 COVID-19，关注疫苗和药物治疗。
J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21.
本文引用的文献
1
Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19.用于治疗轻至中度新型冠状病毒肺炎的中和单克隆抗体
JAMA. 2021 Feb 16;325(7):644-645. doi: 10.1001/jama.2021.0585.
2
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.科学假说与合理药理学：沙库巴曲缬沙坦在 COVID-19 导致的心脏损伤中的应用。
Med Hypotheses. 2021 Feb;147:110486. doi: 10.1016/j.mehy.2021.110486. Epub 2021 Jan 7.
3
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
4
Remdesivir versus ritonavir/lopinavir in COVID-19 patients.瑞德西韦与利托那韦/洛匹那韦用于新冠肺炎患者的对比
Ir J Med Sci. 2021 Aug;190(3):1249-1250. doi: 10.1007/s11845-020-02440-y. Epub 2020 Nov 18.
5
Remdesivir and COVID-19.瑞德西韦与新型冠状病毒肺炎
Ir J Med Sci. 2021 Aug;190(3):1237-1238. doi: 10.1007/s11845-020-02401-5. Epub 2020 Oct 17.
6
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.单次接种 Ad26 疫苗可预防恒河猴感染 SARS-CoV-2。
Nature. 2020 Oct;586(7830):583-588. doi: 10.1038/s41586-020-2607-z. Epub 2020 Jul 30.
7
Sacubitril, valsartan and SARS-CoV-2.沙库巴曲缬沙坦与严重急性呼吸综合征冠状病毒2
BMJ Evid Based Med. 2020 Jul 27. doi: 10.1136/bmjebm-2020-111497.
8
A novel coronavirus outbreak of global health concern.一场引发全球卫生关注的新型冠状病毒疫情。
Lancet. 2020 Feb 15;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9. Epub 2020 Jan 24.
Zotero 插件